Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ZIOPHARM Oncology Inc.    ZIOP

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

ZIOPHARM Oncology Inc. : ZIOPHARM Oncology to Present at the 38th Annual Deutsche Bank Health Care Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
05/22/2013 | 01:48pm CET

BOSTON, May 22, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 38th Annual Deutsche Bank Health Care Conference on Wednesday, May 29th, 2013 at 8:00 a.m. ET at the Westin Boston Waterfront Hotel in Boston, Massachusetts.

To access a live audio webcast of the presentation, please visit the Investor Relations section at www.ziopharm.com. The webcast will be archived for 90 days.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. The Company's clinical programs include:

Ad-RTS-IL-12 is currently being tested in two Phase 2 studies, the first for the treatment of advanced melanoma, and the second in combination with palifosfamide for the treatment of non-resectable recurrent or metastatic breast cancer. Ad-RTS-IL-12 uses synthetic biology to enable controlled delivery of therapeutic interleukin-12 (IL-12), a protein important for enhancing the development of an immune response to cancer. In partnership with Intrexon Corporation, ZIOPHARM's DNA synthetic biology platform employs an inducible gene-delivery system that enables controlled delivery of genes that produce therapeutic proteins to treat cancer. This controlled delivery is achieved by producing IL-12 under the control of Intrexon's proprietary biological "switch" (the RheoSwitch Therapeutic System® or RTS® platform) to turn on/off the therapeutic protein expression at the tumor site.

Palifosfamide (ZIO-201) is a potent, bi-functional DNA alkylating agent that has activity in multiple tumors by evading typical resistance pathways. Palifosfamide is in the same class as bendamustine, cyclophosphamide, and ifosfamide. It is currently being studied in an adaptive Phase 3 study in small cell lung cancer. Enrollment in this study was suspended with 188 subjects randomized, and being followed for overall survival. Data is expected in the first half of 2014.

Indibulin (ZIO-301) is a novel, tubulin binding agent that is expected to have several potential benefits, including oral dosing, application in multi-drug resistant tumors, no neuropathy and a tolerable toxicity profile. It is currently being studied in a Phase 1/2 trial in metastatic breast cancer.

Darinaparsin (ZIO-101) is a novel mitochondrial-and hedgehog-targeted agent (organic arsenic) currently in ongoing studies with Solasia Pharma K.K.

ZIOPHARM's operations are located in Boston, MA. Further information about ZIOPHARM may be found at www.ziopharm.com.

Forward-Looking Safe Harbor Statement:

This press release contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully develop and commercialize our therapeutic products; our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: whether palifosfamide, Ad-RTS-IL-12, darinaparsin, indibulin, or any of our other therapeutic products will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether palifosfamide, Ad-RTS-IL-12, darinaparsin, indibulin, and our other therapeutic products will be successfully marketed if approved; whether any of our other therapeutic product discovery and development efforts will be successful; our ability to achieve the results contemplated by our collaboration agreements; the strength and enforceability of our intellectual property rights; competition from other pharmaceutical and biotechnology companies; the development of, and our ability to take advantage of, the market for our therapeutic products; our ability to raise additional capital to fund our operations on terms acceptable to us; general economic conditions; and the other risk factors contained in our periodic and interim SEC reports filed from time to time with the Securities and Exchange Commission, including but not limited to, our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2013. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.


         Jason A. Amello

         ZIOPHARM Oncology, Inc.


         [email protected]


         Media Contacts:

         David Schull or Lena Evans

         Russo Partners, LLC



         [email protected]

         [email protected]
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
01/11 ZIOPHARM ONCOLOGY INC : Regulation FD Disclosure, Financial Statements and Exhib..
01/11 ZIOPHARM ONCOLOGY INC. : Blog Exposure - ZIOPHARM Updated on Key Clinical Progra..
01/09 ZIOPHARM ONCOLOGY, INC. (NASDAQ : ZIOP) Files An 8-K Financial Statements and Ex..
01/09 ZIOPHARM ONCOLOGY INC : Other Events, Financial Statements and Exhibits (form 8-..
01/09 Ziopharm Oncology Provides Update on Standout Technologies during the 36th An..
2017 ZIOPHARM ONCOLOGY : to Present at the 36th Annual J.P. Morgan Healthcare Confere..
2017 ZIOPHARM to Present at the 36th Annual J.P. Morgan Healthcare Conference
2017 ZIOPHARM ONCOLOGY : Announces Presentation of Data from T-Cell Therapy Programs ..
2017 ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH A..
2017 ZIOPHARM ONCOLOGY : Presents Positive Updated Results of Ad-RTS-hIL-12 Study in ..
More news
News from SeekingAlpha
01/23 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (1/23/2018)
01/22 Midday Gainers / Losers (1/22/2018)
01/22 HEALTHCARE - TOP 5 GAINERS / LOSERS : 15 am (1/22/2018)
01/22 ZIOPHARM riding the Celgene/Juno wave, up 22%
01/12 ZIOPHARM Oncology (ZIOP) Presents At 36th Annual J.P. Morgan Healthcare Confe..
Financials ($)
Sales 2017 6,46 M
EBIT 2017 -58,2 M
Net income 2017 -75,5 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 113x
Capi. / Sales 2018 134x
Capitalization 730 M
Duration : Period :
ZIOPHARM Oncology Inc. Technical Analysis Chart | ZIOP | US98973P1012 | 4-Traders
Technical analysis trends ZIOPHARM ONCOLOGY INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 12,5 $
Spread / Average Target 143%
EPS Revisions
Laurence James Neil Cooper Chief Executive Officer
David M. Mauney Executive VP, Chief Operating & Business Officer
Kevin G. Lafond Principal Financial Officer & Treasurer
Francois Lebel Chief Medical Officer, EVP-Research & Development
Murray F. Brennan Lead Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES13.04%106 315
GENMAB13.75%11 797
BIOVERATIV INC92.49%11 230